Karen Adams Email & Phone Number

Arrivo BioVentures LLC was formed to in-license or acquire and fund drug development projects. We leverage the drug development expertise of our partners Arrivo Management, LLC, which provides the strategic direction, and QuatroBio, LLC, who implements our development initiatives. Our team’s expertise is drug development. Whether we are developing a reformulated product, a new chemical entity, or a biologic, our team has expertise in identifying regulatory strategies to expedite the path to approval and the efficient implementation of the clinical programs themselves. We coordinate with the FDA (and other regulatory bodies) early and often to gain agreement on the development programs for our products, minimizing surprises and speeding implementation.While our past companies were built around project financing specific drug candidates, it is the intent of Arrivo BioVentures to diversify investment across four to six drug candidates, creating a portfolio of development projects that can have a greater likelihood of development milestone success and regulatory approval over time.Our strategy is simple – identify products for our pipeline that we can expedite through the drug development process while minimizing the regulatory and technical risk associated with the program.In May 2016 we closed on a preferred financing totaling $49 million in committed capital. Consistent with the management team’s previous companies, Arrivo’s team will source and acquire development candidates in or ready for the early stages of human clinical trials and move the projects through clinical proof-of-concept and the next significant valuation inflection point.

QuatroBio is the management company for two early-stage life sciences companies. The first, Midnight Pharma LLC, is developing a novel product for the treatment of insomnia and is in Phase 2. The second, Velo Bio LLC, is developing an orphan drug for the treatment of severe preeclampsia in pregnant women (DIF program), also in Phase 2. In July 2015, Velo announced that it had entered into an agreement that grants AMAG Pharmaceuticals, Inc. an exclusive option to acquire the rights to Velo's orphan drug candidate at the conclusion of a Phase 2b/3a clinical trial. AMAG made an upfront payment of $10 million to Velo for the option to acquire global rights to the DIF program.QuatroBio was founded by the same management team which founded (and subsequently sold) Aerial BioPharma, Neuronex, and Addrenex. All successful drug development companies in the RTP area of North Carolina.I am continuing my role as CFO, as I have for the predecessor companies, to provide financial guidance, structure and support as the team advances the drug development programs in Midnight and Velo.

Consulting practice providing part time CFO level support to privately funded businesses.

Durham, North Carolina, Us

Durham, North Carolina, Us

TARGET PharmaSolutions is a clinical information company that is focused on providing a more efficient solution for fulfilling post-marketing commitments than traditional Phase 4 trials. By forming a collaborative community that includes Pharma Manufacturers, Key Opinion Leaders, regulatory agencies, and patient advocacy groups, TARGET is able to provide high quality clinical data that is reflective of real-world utilization.I have been engaged by Target to provide financial guidance, structure and support as the Company enters the marketplace and considers funding opportunities.

Raleigh, Nc, Us

Contego Medical, LLC, is developing a portfolio of novel medical devices that address clear unmet needs in the cardiovascular and peripheral vascular space. By integrating filter based embolic protection with treatment on the same platform, Contego Medical’s portfolio of devices are poised to transform the field of cardiovascular and endovascular intervention by making existing procedures safer without increasing complexity or compromising performance. Having recently secured $5.6M in a Series B financing, I have been engaged by Contego to provide financial guidance and support as the Company develops several new and innovative products with its next-generation Integrated Embolic Protection platform.

Exodos Life Sciences, located in Chapel Hill, North Carolina, is a pharmaceutical development partnership that focuses on adding value to exciting new product concepts by advancing drugs through preclinical and early clinical proof-of-concept (POC). The Company is expert in delivering safe and effective medications for the successful treatment of pain and inflammation.The clinical results of Exodos Life Sciences’ sister company, Achelios, have been significant to date and show that its medication formulations offer superior skin permeation compared to many other commercial brands. The Achelios innovative topically delivered drug formulations greatly enhance the permeation of selective agents across human skin, between 4 and 9 times that of leading commercial brands. Their strategy is to establish a clinical stage drug development pipeline that addresses a significant unmet medical need and to move rapidly to proof-of-concept.I have been engaged by Exodos and its sister company, Achelios, to provide financial guidance, support and structure as the Companies continues their drug development programs.

EnviCor Enterprises LLC is a High Quality Rotational Molder of Plastic Products & Manufacturer of the SmartTank for liquid management. I was engaged by EnviCor in early 2010 to prepare the Company for outside investment which it successfully completed in November 2011. EniCor raised $850,000 for expansion from two North Carolina investment firms to further develop and market their SmartTank, a high-tech way to store and remove used cooking oil from restaurants that includes sensors and wireless communications. I provided financial advice and support to the growing Company and management team over the course of 5 years. This included the implementation of product line cost reporting and the creation of a dynamic financial model to reflect an evolving business model.

Aerial BioPharma is a group of entrepreneurs who have come together to change the way investors and industry think about drug development. Aerial is a privately held biopharmaceutical company focused on developing biologics and small molecules for conditions that are affected by processes in the Central Nervous System. The company was founded in January of 2011 by the management team from Neuronex Inc. and Addrenex Pharmaceuticals, both successful start-ups based in the Research Triangle Park area of North Carolina.In January 2014 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Aerial BioPharma, LLC announced that the companies had signed a definitive agreement under which Jazz Pharmaceuticals has acquired rights to ADX-N05, a novel compound in clinical development for the treatment of excessive daytime sleepiness in patients with narcolepsy. Under the agreement, Aerial received an upfront payment of $125 million.

Morrisville, North Carolina, Us

Neuronex, Inc. is a privately held biopharmaceutical company focused on developing drugs that treat CNS diseases and disorders. The company was founded in April of 2010 by three members of the management team of Addrenex Pharmaceuticals, a successful start-up specialty pharmaceutical company acquired by Shionogi Pharma in November of 2009. In December 2012 Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that the Company completed the acquisition of Neuronex, Inc., specifically to acquire the proprietary nasal spray formulation of diazepam under development by the Company. Under the terms of the agreement, Acorda paid $6.8 million to Neuronex to complete the acquisition.

Durham, Nc, Us

AlphaMed Press is a premier independent publisher with three internationally peer-reviewed journals dedicated to advancing knowledge and education in their focused disciplines: The Oncologist; STEM CELLS, and STEM CELLS Translational Medicine. Founded in 1983, they have offices in Durham, NC; San Francisco, CA; and Belfast, Northern Ireland.I was engaged by AlphaMed to improve financial reporting with the goal of providing information on the financial performance of each of the Company's publications. This was accomplished and enabled to Company to make more informed decisions for each of its journals as individual profit centers.

Addrenex focuses on products related to the adrenergic system, the system that regulates functions such as stress, pain, sleep and blood pressure.In November 2009 Addrenex was acquired for $29 million by Sciele Pharma Inc., an Atlanta pharmaceutical company that had already licensed three of Addrenex’s products and was one of its existing investors.

Cambridge, Ma, Us

Millennium is a leading biopharmaceutical company based in Cambridge, Massachusetts. The Company markets Velcade (bortezomib) for injection, a cancer product, and has a growing clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation.In February 2002 the Company merged with COR Therapeutics — among the largest such mergers in the history of the biotech industry at that time. I was originally engaged to assist the Corporate Controller to prepare for the merger and following to the merger, to assist in the integration of the two entities' financial reporting systems. This engagement lead to my role as acting Assistant Controller, a role which previously did not exist.

Controller for manufacturer and importer of women's clothing.

Controller of women's specialty retail store - Six stores located in Boston and Connecticut.

Memphis, Tennessee, Us

Performed financial and operational audits world-wide at paper mills, saw mills, container plants and at other Company operations. International audits included locations in Cali, Columbia, Arles, France and Milan, Italy where I was the Supervisor of the multi-location audit.